Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(3):175-176; doi:10.1093/jnci/93.3.175
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Finkelstein, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Finkelstein, J. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 3, 175-176, February 7, 2001
© 2001 Oxford University Press

NEWS

FDA Panel Recommends Two New Cancer Drugs for Approval

Joel B. Finkelstein

The U.S. Food and Drug Administration in January approved the drug Femara for first-line treatment of advanced breast cancer. The approval of the aromatase inhibitor was based on the recommendations of the agency’s panel of cancer experts.



View larger version (140K):
[in this window]
[in a new window]
 

 
Femara (letrozole tablets) is now an option for postmenopausal women diagnosed with advanced breast cancer. The panel’s recommendation was based on a multinational clinical trial of 916 women. . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?